Abstract
Guenther et al. have developed a protease-activatable AAV provector to target diseased tissue microenvironments exhibiting elevated extracellular protease activity. The provector delivers transgenes to high-MMP-activity regions of the damaged heart following a myocardial infarction, with concomitant decreased delivery to many off-target organs, including the liver.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 611-622 |
| Number of pages | 12 |
| Journal | Molecular Therapy |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 6 2019 |
| Externally published | Yes |
Keywords
- AAV
- activatable
- adeno-associated virus
- cardiac gene therapy
- gene delivery
- gene therapy
- inflammation targeting
- matrix metalloproteinase
- myocardial infarction
- provector
- stimulus responsive
- viral vector
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
Fingerprint
Dive into the research topics of 'Protease-Activatable Adeno-Associated Virus Vector for Gene Delivery to Damaged Heart Tissue'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS